Letter to the editorThe effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction
References (18)
- et al.
American Academy of Allergy, Asthma & Immunology Work Group report: exercise-induced asthma
J Allergy Clin Immunol
(2007) - et al.
Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
J Pediatr
(1998) - et al.
Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma
J Allergy Clin Immunol
(2008) - et al.
Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction
Ann Allergy Asthma Immunol
(2001) - et al.
Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses
J Allergy Clin Immunol
(2003) - et al.
Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma
Chest
(2008) - et al.
Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma
J Allergy Clin Immunol
(2006) - et al.
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
J Allergy Clin Immunol
(2005) - et al.
Effect of fluticasone/salmeterol administration via a single device on exercise-induced bronchospasm in patients with persistent asthma
Ann Allergy Asthma Immunol
(2005)
Cited by (19)
Co-electrospraying technology as a novel approach for dry powder inhalation formulation of montelukast and budesonide for pulmonary co-delivery
2020, International Journal of PharmaceuticsWork Group Report: Perspectives in Diagnosis and Management of Exercise-Induced Bronchoconstriction in Athletes
2020, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :As with SABAs, tolerance can also develop with long-acting β2-agonists.5 Leukotriene receptor antagonists (montelukast) can be administered daily for prophylaxis, as an add-on therapy to inhaled steroids, or given 1 to 2 hours before exercise, which has shown efficacy in preventing EIB for up to 12 to 24 hours.79-83 Other leukotriene receptor antagonists including zafirlukast and zileuton, a 5-lipoxygenase inhibitor, have also been shown to be effective in EIB.
Cough in exercise and athletes
2019, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :If low doses of ICS do not achieve asthma control, the addition of another controller drug should be considered, such as a long-acting inhaled β2-agonist or a leukotriene-receptor antagonist (LTRA). This last can help reduce EIB [96] and has protective effects against the bronchoconstriction caused by exposure to pollutants [97]. Cromolyn sodium and nedocromil sodium protect against EIB, but inhaled β2-agonists are more effective and can be used 5–10 min before exercise.
Pharmacologic Strategies for Exercise-Induced Bronchospasm with a Focus on Athletes
2018, Immunology and Allergy Clinics of North AmericaExercise-induced bronchoconstriction update—2016
2016, Journal of Allergy and Clinical ImmunologyRole of Cells and Mediators in Exercise-Induced Bronchoconstriction
2013, Immunology and Allergy Clinics of North AmericaCitation Excerpt :These results clearly demonstrate a role for CysLTs in the pathogenesis of EIB but also indicate that the protection from EIB is incomplete, suggesting that mediators other than the CysLTs may play a significant role and that the loss of bronchoprotective mediators may be important. A recent study found that an ICS added to a CysLT1 antagonist had improved efficacy over treatment with either an ICS or CysLT1 antagonist alone.53 Mast cells and eosinophils are strongly implicated as the cellular sources of CysLTs and other eicosanoids such as PGD2 in EIB.
This study was sponsored by Merck Frosst.
Disclosure of potential conflict of interest: P. M. O'Byrne has served on advisory boards for AstraZeneca, GlaxoSmithKline, Boehringer, Merck, and Almiral; has received speakers' honoraria from AstraZeneca; and has received research support from AstraZeneca, Asmacure, Genentech, Amgen, ONO, and AIM. The rest of the authors declare that they have no relevant conflicts of interest.